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1. Introduction 
T lymphocytes like all blood cells are progenies of a single multipotent hematopoietic stem 
cell (HSC). The existence of HSCs was proven by Till and McCulloch in 1961 when bone 
marrow cells injected into irradiated mice formed multilineage colonies in their spleens. 
These cells were called colony forming units (CFU-S) and they have potential for self-
renewal and differentiation into all types of blood cells(Till and McCulloch 1961; Wu et al. 
1968). For lymphocyte development HSCs migrate from the bone marrow, differentiate in 
the thymus into immunocompetent cells and seed the peripheral lymphatic organs.  This 
process occurs during fetal development (for review see (Godin and Cumano 2002), but also 
during the adult life of an individual since T lymphocytes have to be continuously 
replenished. Transplantation experiments proved that thirty hematopoietic stem cells are 
sufficient to save 50 percent of lethally irradiated mice, and to reconstitute all blood cell 
types in vivo (Spangrude et al. 1988). Because it is extremely important to produce 
immunocompetent T cells the process of their maturation and development is strictly 
regulated and is succumb to very strict check points at several stages of differentiation. In 
this context we’ll discuss Ikaros family transcription factors as major regulators of T 
lymphocyte development. 
2. Committed lymphocyte precursor 
For a long time it has been postulated analogously to committed myeloid precursors that 
there is a committed lymphocyte precursor. However the first experiments that showed the 
existence of a committed lymphocyte precursor was described in the early 90tis when a new 
population of cells in the thymus was found and its features described (Wu 1991; Wu et al. 
1991). These cells expressed most markers of the multipotent hematopoietic stem cells like 
Thy-1lowCD44+H2k+Sca-1+ but they expressed Sca-2 and low levels of CD4. These cells were 
negative for all mature blood cells markers lymphocytes (CD8-CD3-Ig-), macrophages (Mac-
1-), granulocytes (Gr-1-) and erhytrocytes (TER119-), lineage negative, (Lin- cells). Their Ig 
and TCR receptor genes were in germline configuration. The described precursors represent 
0.05% of the cells in an adult mouse thymus. If the cells were sorted and transferred by 
intrathymic injections (i.t.) into lethally irradiated congenic mice they developed into all 
thymic subpopulations, first CD4-CD8- (double negatives, DN) thymocytes, than into 
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CD4+CD8+ double positives which give rise to mature CD4+ and CD8+ lymphocytes. Mature 
cells derived from the CD4low precursors seeded the spleen, lymph nodes and bone marrow. 
The reconstitution potential of the described precursors was lower and the time for 
development was shorter when compared to the multipotent hematopoietic stem cells from 
the bone marrow. These experiments proved that the CD4low precursors in the thymus can 
develop into T lymphocytes. Because of their resemblance to the multipotent progenitors 
from the bone marrow it was important to answer the question whether their potential was 
restricted only to develop into T lymphocytes. Therefore we transplanted these cells into the 
periphery by injecting them intravenously (i.v.) into lethally irradiated congenic animals. 
Their progenies were found to develop into T lymphocytes similarly to the results obtained 
by direct i.t. transplantation experiments. When injected intravenously they also developed 
into B lymphocytes but there were no myeloid progenies. During fetal development these 
cells were detected from day 14 in the fetal thymus but only after birth their function was 
comparable to the adult ones(Antica et al. 1993). In the bone marrow the CD4low precursor 
cells were described, but their function was not lymphocyte restricted (Antica et al. 1994a). 
Further studies showed that in the bone marrow the marker that could differentiate the 
lymphoid precursor cells from the multipotent precursors was IL7Rα (Kondo et al. 1997). 
This population, called common lymphoid precursor (CLP) is characterized by Lin− Thy-
1−Sca-1loc-Kitlo IL-7R+ and possess rapid and prominent short-term lymphoid-restricted (T, 
B, and NK cells) reconstitution activity. However, this progenitor population clonally 
produces both B and T lymphocytes, but have little myeloid potential in vivo. A recently 
developed bioinformatics method, called Mining Developmentally Regulated Genes, which 
mines the publically available microarray data to identify genes that are up- or down-
regulated within a developmental pathway was applied to identify surface proteins that 
distinguish functional CLPs from other progenitors (Inlay et al. 2009; Sahoo et al. 2010). A 
surface marker Ly6d dissects the CLP population in two and shows that it consists of a 
mixture of all lymphoid progenitor cells (ALP) which retain B and T lymphoid potential, 
and BLP (B cell biased lymphoid progenitors). This manuscript offers strong support for the 
validity of our earlier conclusions. However, ALPs still keep low myeloid potential 
indicating that ALPs are either a mixture of the CD4low precursor cells and myeloid 
progenitors or is a single population but at an earlier developmental stage and still 
multipotent(Wu et al. 1991; Antica et al. 1993; Antica et al. 1994b; Inlay et al. 2009). Here we 
also stress the necessity and importance of in vivo assays for the determination of 
physiologic lineage potentials since it has been recently shown that in vitro assays can 
misrepresent in vivo lineage potentials of murine lymphoid progenitors(Richie Ehrlich et al. 
2011). 
From the clinical point of view defining the earliest lymphoid precursor is important for a 
rapid engraftment and protection from infections after hematopoietic stem cell 
transplantation in chemotherapy or irradiation compromised patients (Arber et al. 2003; 
Holländer et al. 2010).  
3. Ikaros transcription factors 
Mechanisms and factors that regulate lymphocyte development from stem cells have to be 
very accurate since any alteration of this process may lead to serious diseases like leukemia.  
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Transcription factors from the Ikaros family play an essential role in the commitment of 
hematopoietic progenitors into the lymphoid lineage as well as in the choice of effector 
functions at later stages of development(Georgopoulos 1994; Sun et al. 1996; Wang et al. 
1998; Cortes et al. 1999). Their role has been addressed by gene targeting and such gene 
inactivation studies have identified Ikaros, Aiolos and Helios as transcription factors 
required for the maturation of lymphocytes(Morgan 1997; Hahm 1998; Kelley 1998). It has 
been shown that mice homozygous for a deletion in these genes undergo remarkable 
changes in their lymphocyte populations and also those ageing animals with the same 
mutation develop lymphoproliferative disorders. A number of studies show that Ikaros 
genes in both mice and human malignancies might be deregulated (Winandy et al. 1995; 
Nichogiannopoulou et al. 1999; Nakase et al. 2000; Nakayama et al. 2000; Nakase et al. 
2002; Rebollo and Schmitt 2003; Dovat et al. 2005; Mullighan et al. 2008; Matulic et al. 
2009; Billot et al. 2010). Therefore we addressed the question whether a combination of 
transcription factor failures may contribute to the development of human lymphoma. We 
amplified human mRNA from formalin fixed paraffin embedded tissues from lymphoma 
patients in order to have consistent and well defined groups of patients. Hence, we were 
able to analyze Ikaros, Aiolos and Helios mRNA from archive tissue specimens from 
patients with Hodgkin’s and non- Hodgkin’s lymphoma and follicular hyperplasia 
(Antica et al. 2008; Antica et al. 2010). Further we and others show a deregulation in 
human leukemia. Acute lymphoblastic leukemia (ALL) is characterized by the 
Philadelphia chromosome (Ph) which encodes the BCR-ABL1 tyrosine kinase, the most 
frequent cytogenetic abnormality (∼25–30% of cases)(Mancini et al. 2005). Deletion of the 
IKAROS gene (IKZF1) was found in 83.7% cases of BCR-ABL1 ALL, but not in chronic-
phase CML(Mullighan et al. 2008). Posttranscriptional regulation of alternative splicing of 
Ikaros was associated with resistance to tyrosine kinase inhibitors (TKIs) in Ph/positive 
acute lymphoblastic leukemia (ALL) patients (Iacobucci et al. 2008). Further, IKZF1 
deletions are likely to be a genomic alteration that significantly affects the prognosis of 
Ph-positive ALL in adults (Martinelli et al. 2009). Further, when Ikaros expression was 
analyzed by real time RT-PCR the quantitative distribution of mRNA level in 
hematopoietic cells of patients with lymphocytic leukemia was similar but a clear 
difference among groups was due to Aiolos lower expression in all types of acute 
leukemia(Antica et al. 2007). The mechanisms involved have been tested in the mouse 
model. It has been found that pre-BCR induces Ikaros to inhibit the proliferation of 
Philadelphia chromosome-positive B-ALL cells (Trageser et al. 2009). Pre–B cell 
receptor/IKAROS-induced cell cycle arrest can be reversed by dominant-negative Ikaros 
splicing variant IK6(Trageser et al. 2009). A possible mechanism of Ikaros suppression has 
been described by Ma et al. Their experiments on mice show that Ikaros inhibits c-Myc as 
a direct target, resulting in inhibition of pre B-lymphocyte proliferation (Ma et al 2010).  
In the last ten years a new system, besides fetal thymic organ cultures (FTOC) or 
reaggregation cultures, for T cell growth in vitro has been developed. It has been shown 
that OP9 stromal cells transfected with the Notch ligand delta like 1 DL1 (OP9-DL1) can 
support T lymphocyte differentiation in vitro ( Schmitt and Zúńiga-Pflücker 2002). This 
new technology provided a powerful tool for analyzing developmental phases from 
multipotent stem cells to mature T lymphocytes at single cell level in vitro and allowed a 
better understanding of the processes underlying development. However, there are still a 
lot of unanswered and exciting questions to be solved. Who is regulating Ikaros and 
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Notch? How transcription factors regulate development with their partners and DNA 
where and how do they interfere with their partners, and DNA, how can we identify 
targets for new drugs and finally how can we produce T cells in vitro for practical 
applications and regenerative medicine? 
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